All lobbying filings
The KPM Group DC LLC
The KPM Group DC LLC filed a Q3 termination report for Inozyme Pharma on October 17, 2025, reporting no lobbying activity.
Lobbying for Inozyme Pharma · Treatments for PPi-Adenosine Pathway, ENPP1 Deficiency, ABCC6 Deficiency, & calciphylaxis.
Filing · LD-2 quarterly report
Q3 terminationNo activity
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 17, 2025
Money reported
None
Registrations and no-activity reports carry no figure.
Client based in
Massachusetts
Representation ended
Jul 1, 2025
The registrant reported terminating its work for this client.
Lobbying activity
0
No itemized activity in this filing.